| 2026-10-26 17:09 |
8-K |
["3.02", "7.01", "8.01"] |
other |
0.05
|
Private placement financing and milestone achievement in EQ504 trial; no M&A signals. |
SEC · detail |
| 2026-10-05 17:06 |
8-K |
["8.01"] |
other |
0.05
|
Clinical trial approval announcement for EQ504; no M&A signals present. |
SEC · detail |
| 2026-08-13 16:10 |
8-K |
["2.02", "9.01"] |
other |
0.05
|
Routine earnings announcement for Q2 2026; no M&A signals present. |
SEC · detail |
| 2026-05-29 16:05 |
8-K |
["5.07", "9.01"] |
other |
0.15
|
Routine annual shareholder meeting with director elections, reverse split authorization, and share increase—no M&A signals. |
SEC · detail |
| 2026-05-13 16:05 |
8-K |
["2.02", "9.01"] |
other |
0.05
|
Routine Q1 2026 earnings announcement with no M&A-related language or strategic signals. |
SEC · detail |